CareDx, Inc (FRA:1K9)

Germany flag Germany · Delayed Price · Currency is EUR
15.11
-0.13 (-0.85%)
Last updated: Dec 1, 2025, 8:11 AM CET
-35.26%
Market Cap792.63M
Revenue (ttm)305.12M
Net Income (ttm)60.05M
Shares Outn/a
EPS (ttm)1.04
PE Ratio13.20
Forward PE17.77
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume0
Open15.11
Previous Close15.24
Day's Range15.11 - 15.11
52-Week Range9.83 - 24.43
Betan/a
RSI60.84
Earnings DateFeb 27, 2026

About CareDx

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 1998
Employees 650
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1K9
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiat...

7 days ago - Business Wire

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transp...

7 days ago - Wallstreet:Online

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

21 days ago - Business Wire

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization ...

24 days ago - Business Wire

CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization ...

25 days ago - Business Wire

CDNA: BTIG Raises Price Target to $25, Maintains Buy Rating | CDNA Stock News

CDNA: BTIG Raises Price Target to $25, Maintains Buy Rating | CDNA Stock News

25 days ago - GuruFocus

After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results

(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session ...

27 days ago - Nasdaq

CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance

CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance

27 days ago - GuruFocus

CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript

CareDx, Inc (CDNA) Q3 2025 Earnings Call November 4, 2025 4:30 PM ESTCompany ParticipantsTina JacobsenJohn Hanna - President, CEO & DirectorNathan Smith...

27 days ago - Seeking Alpha

Q3 2025 CareDx Inc Earnings Call Transcript

Q3 2025 CareDx Inc Earnings Call Transcript

27 days ago - GuruFocus

CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for CareDx (CDNA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar...

27 days ago - Nasdaq

CareDx Inc (CDNA) Q3 2025 Earnings: EPS of $0. ...

CareDx Inc (CDNA) Q3 2025 Earnings: EPS of $0.03 Beats Estimate, Revenue Surpasses Expectations at $100.1 Million

27 days ago - GuruFocus

CareDx Announces Third Quarter 2025 Financial Results

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthc...

27 days ago - Wallstreet:Online

CareDx Announces Third Quarter 2025 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically...

27 days ago - Business Wire

CareDx Q3 2025 Earnings Preview

4 weeks ago - Seeking Alpha

CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect

CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect

4 weeks ago - GuruFocus

CareDx Appoints Jeffrey Teuteberg As CMO

(RTTNews) - CareDx, Inc. (CDNA), a precision medicine company, said on Monday that it has appointed Jeffrey John Teuteberg as its Chief Medical Officer with effect from October 1.

5 weeks ago - Nasdaq

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healt...

5 weeks ago - Wallstreet:Online

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinica...

5 weeks ago - Business Wire

CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiat...

5 weeks ago - Business Wire

CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiate...

5 weeks ago - Business Wire

CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...

5 weeks ago - Business Wire

CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization ...

2 months ago - Business Wire

CareDx Issues Comment Letter on Draft LCD Policy

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

3 months ago - Business Wire